The FDA granted orphan-drug designation to ENMD-2076, EntreMed's treatment candidate for acute myeloid leukemia. The drug previously gained orphan-drug status as a treatment for ovarian cancer and multiple myeloma.
Published in Brief:
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||